Allyson Wheaton, MD
Psychiatry · Cedar Rapids, IANPI 1063491645
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 49.4% of the total. Reporting peaked in 2024 at $415 and has fallen 60.6% since, to $163 in 2025.
Across 85 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$865
- Otsuka America Pharmaceutical, Inc.$220
- Adlon Therapeutics L.p.$129
- Corium, LLC$115
- Johnson & Johnson$85
- Teva Pharmaceuticals USA, Inc.$83
- plus $254 from 9 others
What the payments were for
- Food & beverage$1,743100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 50 | $865 |
| Otsuka America Pharmaceutical, Inc. | 3 | $220 |
| Adlon Therapeutics L.p. | 7 | $129 |
| Corium, LLC | 6 | $115 |
| Johnson & Johnson | 3 | $85 |
| Teva Pharmaceuticals USA, Inc. | 5 | $83 |
| AbbVie | 1 | $79 |
| Ironshore Pharmaceuticals Inc. | 3 | $46 |
| Alkermes, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Brainsway USA Inc | 1 | $21 |
| Harmony Biosciences LLC | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$283
How this compares
$1,749 in reported general payments places this provider in the 85th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 30 | $37,953 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $27,410 |
| TrintellixVortioxetine Hydrobromide | 54 | $24,881 |
| VraylarCariprazine Hcl | 11 | $15,645 |
| Aripiprazole | 129 | $15,396 |
| VyvanseLisdexamfetamine Dimesylate | 27 | $10,675 |
| Adzenys Xr-OdtAmphetamine | 12 | $5,826 |
| QuviviqDaridorexant Hcl | 11 | $5,456 |
| QelbreeViloxazine Hcl | 13 | $4,662 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 30 | $3,255 |
| Vilazodone Hcl | 38 | $3,089 |
| Quetiapine Fumarate | 114 | $2,752 |
| Dextroamphetamine Sulfate | 16 | $2,742 |
| Duloxetine Hcl | 149 | $2,053 |
| Atomoxetine Hcl | 12 | $1,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $220 | $37,95330 claims |
| Alkermes, Inc.Lybalvi | $22 | $27,41017 claims |
| AbbVieVraylar | $79 | $15,64511 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $865 | $4,66213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Cedar Rapids
- Alan WhittersCedar Rapids$170K
- Dwight SchroederCedar Rapids$13K
- Jacob MillerCedar Rapids$2K
- Jeffrey WilharmCedar Rapids$2K
- Rebecca WolfeCedar Rapids$1K
- Frank BabcockCedar Rapids$1K
- Sundara Rameshwar Munagala VenkataCedar Rapids$867
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.